Liver Health Management
Cloud-based solution to assist clinicians in providing comprehensive liver care.
Learn more
FibroScan® GO
The state-of-the-art non-invasive solution for liver disease management, affordable to all.
Powered by LSM by VCTE™ and CAP™ for liver fibrosis and steatosis management.
Supported by 6 270+ peer reviewed publications and 250+ guidelines.
Ideal point-of-care solution for primary care office-based settings.
An ideal solution for point-of-care use
Pay-per-exam solution.
A full ecosystem of solutions,including service coverage
and support.
Centralized data management and user-friendly interface.
A small and compact device for easy integration at a busy practice
Enhanced care for your patients
Simple, fast assessment of your patients’ liver health.
Innovative, next generation technology, offers simplified exams on all morphologies.
Immediate results for informative and straightforward provider/patient consultations.
Identify, assess and monitor patients at risk for liver disease right in your office
A cloud-based solution offering you Everyday support
Automate the transfer of FibroScan® results to the LHM platform to help you make data-driven decisions.
Access historical patient data and generate reports easily shared with patients and referring physicians.
Enhance examinations with FibroScan® based Scores and interpretation tools.
Monitor and manage your patients’ liver disease with patient history and clinical care pathway tools right in the LHM platform.
Scores interpretation available on the LHM platform
Enhancing FibroScan® liver disease assessment with biological markers
Tried & Trusted
Without FibroScan® technology, we felt that our patients would be missing an important service and that many patients with advanced liver disease and significant health risk would go unrecognized.
The biggest advantage of offering FibroScan® GO in my office is that my patients appreciate the additional step we take for their care to prevent long term health complications. They also become more focused on weight loss after knowing the risks of having fatty liver and seeing their FibroScan results.
A complete solution including proactive and dedicated support
Assists with onsite installation and training.
Includes maintenance, annual calibration of probes and both software upgrades and updates.
Easy access to continuous training and users community with Echosens Academy.
A state-of-the-art FibroScan®
Quickly and easily assess liver stiffness using LSM by VCTE™ and CAP™ for liver fibrosis and steatosis management.1,2,3
Ideal point-of-care solution for primary care office-based settings.
Equipment compatible with an S+ probe (sold separately).
The FibroScan® 230 is intended to measure liver stiffness (E) using Vibration Controlled Transient Elastography (VCTE™) at 50 Hz shear wave frequency and liver ultrasound attenuation (CAP™)* at 3.5 MHz. FibroScan liver stiffness measurements (LSM) by VCTE™ may aid the physician in determining the likelihood of cirrhosis and may be used, taken in context with other clinical and laboratory data, as an aid in the assessment of liver fibrosis. FibroScan CAP™ measurements may be used, taken in context with other clinical and laboratory data, as an aid in the assessment of hepatic steatosis. FibroScan® is indicated as a non-invasive aid to clinical management diagnosis and monitoring of adult and pediatric patients with confirmed or suspected liver disease, as part of an overall assessment of the liver. Results in the pediatric population should be interpreted while considering the clinical condition and the overall patient profile. The FibroScan® device is intended for use by healthcare professionals in hospitals, clinics or any facility where healthcare is provided.
*CAP™ refers to ultrasound attenuation coefficient (originally defined as Controlled Attenuation Parameter).
All personal and health data generated by the FibroScan® GO solution is managed in compliance with HIPAA regulations. Data located on Echosens Cloud is managed by an ISO27001 certified organization.
1. Wong VW, et al. Noninvasive biomarkers in NAFLD and NASH – current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018;15(8):461-478.
2. European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-264.
3. Steadman R, et al. A health technology assessment of transient elastography in adult liver disease. Can J Gastroenterol. 2013;27(3):149-158.
Already a FibroScan GO® user?
To access the FibroScan® 230 user guides, connect to the LHM platform (Echosens Cloud)
Learning Center > FibroScan® GO
Going further in the management of liver disease
FibroScan® Probes
Optimize measurement accuracy on all patients of varying size
Learn more
FibroScan® by echosens
The non-invasive solution for comprehensive management of liver health
Learn more
EASL Clinical Practice Guidelines
Non-invasive evaluation of liver disease severity and prognosis
Learn more
